flu vaccine
Coverage of flu vaccine in the Nexus archive.
- Opinion: CDC leadership continues to try manufacture a scientific debate on vaccines where none exists
The article criticizes CDC leadership for attempting to create a scientific debate on vaccines where none exists, highlighting the consequences of not trusting public health tools for monitoring vaccine effectiveness.
- EU hits France's Sanofi with flu vaccine antitrust probe
The European Union has initiated an antitrust probe against France's Sanofi, a drugmaker, over its flu vaccine. The article notes Sanofi's logo at a Paris technology fair.
- Mandatory flu shots for all military recruits as outbreak sickens nearly 300
The Pentagon has reinstated mandatory flu vaccinations for military recruits after Defense Secretary Pete Hegseth made the shot optional in April. This decision follows a flu outbreak at Lackland Air Force Base that sickened nearly 300 people, though officials stated the mandate was unrelated to the outbreak.
- Air Force base now requires flu vaccine after 160 troops infected, 1 dead
About 160 troops at Lackland Air Force Base in San Antonio, Texas have been infected with influenza over the past three weeks, including one trainee's death that is still under investigation. The base now requires a flu vaccine.
- Scores fall ill at Air Force base after Hegseth makes flu vaccine optional
Scores of recruits at an Air Force base fell ill following an outbreak linked to flu vaccine being made optional. The illness spread rapidly in a Basic Military Training wing where recruits share close living and dining spaces.
- First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot
Moderna is seeking FDA approval for its new flu vaccine, mFlusiva, targeting individuals 50 and older. The FDA advisory committee meeting is a critical step toward a final decision before the winter flu season.
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
The FDA is considering Moderna's first mRNA-based flu vaccine, mFlusiva, for people 50 and older. A study showed it reduced flu cases by 27% compared to a standard vaccine, but data on frail older adults and those with weak immune systems is lacking. A prior FDA official disputed the vaccine's comparison to a high-dose brand, but the application was later accepted.
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
The FDA advisory panel is evaluating Moderna's first mRNA-based flu vaccine, mFlusiva, for approval in adults 50 and older. The vaccine, which showed a 27% reduction in flu cases compared to a standard-dose vaccine in a 40,000-person study, faces scrutiny over its study design but has received a favorable FDA review with no safety concerns noted.
- Flu vaccine no longer mandatory for soldiers, says US military chief
The US military has made the flu vaccine non-mandatory for soldiers, citing 'medical autonomy' as the reason. Pentagon chief Pete Hegseth criticized the previous mandate as 'overreaching'.
- Hegseth ends mandatory flu vaccine for service members
Defense Secretary Pete Hegseth announced the Pentagon is ending mandatory flu vaccines for service members, citing 'medical autonomy' and 'freedom to express religious convictions' as reasons for the policy change. The new policy allows service members to opt out of the vaccine requirement.
- ‘Uncharted territory’: uncertainty as US vaccine guidance falls apart under Trump
The CDC's vaccine recommendations, including flu and Covid shots, were revoked due to changes by the Trump administration, with a judge's stay halting further modifications. Uncertainty now surrounds vaccine access and future development as the halted ACIP committee faces no new recommendations.
- Common vaccine slashes Alzheimer's disease risk when dose is increased
A study led by UTHealth found that a high-dose flu vaccine reduces Alzheimer's risk by 55% in adults over 65 compared to standard doses. The research highlights a potential link between stronger vaccines and lower Alzheimer's risk, though causation remains unproven.